Todd Severin, MD
Ophthalmology · San Ramon, CANPI 1144225343
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $59,832 of the $87,513 with a category attached, or 68.4%. Carl Zeiss Meditec, Inc. accounts for 67.3% of it on its own, with 26 other manufacturers making up the rest. Reporting peaked in 2019 at $69,994 and has fallen 98.8% since, to $828 in 2025. Among ophthalmology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 306 payments — averaging $285.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Carl Zeiss Meditec, Inc.$59K
- Aerie Pharmaceuticals, Inc.$11K
- Alcon$7K
- Bausch & Lomb, A Division Of Bausch Health US, LLC$5K
- AbbVie$2K
- Johnson & Johnson Surgical Vision, Inc.$1K
- plus $3K from 21 others
What the payments were for
- Consulting fees$59,83268%
- Speaking & faculty fees$20,26623%
- Travel & lodging$780%
- Food & beverage$7,1958%
- Education$980%
- Gifts$450%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Carl Zeiss Meditec, Inc. | 4 | $58,924 |
| Aerie Pharmaceuticals, Inc. | 28 | $10,546 |
| Alcon | 34 | $6,874 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 27 | $5,237 |
| AbbVie(2 entities) | 101 | $2,088 |
| Johnson & Johnson Surgical Vision, Inc. | 4 | $1,159 |
| Novartis | 13 | $425 |
| Sun Pharmaceutical Industries Inc. | 19 | $396 |
| Oyster Point Pharma, Inc. | 12 | $357 |
| Bausch & Lomb Americas Inc. | 16 | $331 |
| Biotissue Holdings Inc. | 8 | $230 |
| Eyevance Pharmaceuticals LLC | 5 | $146 |
| Thea Pharma Inc. | 7 | $138 |
| Sight Sciences, Inc. | 6 | $137 |
| Harrow Eye, LLC | 2 | $94 |
| Mallinckrodt Hospital Products Inc. | 3 | $74 |
| Kala Pharmaceuticals, Inc. | 4 | $67 |
| Iridex Corporation | 3 | $65 |
| Glaukos Corporation | 1 | $39 |
| Rxsight Inc | 2 | $38 |
| Dompe US, Inc. | 1 | $30 |
| Amgen | 1 | $28 |
| Beaver-visitec International, Inc. | 1 | $25 |
| Mallinckrodt Enterprises LLC | 1 | $22 |
| Tarsus Pharmaceuticals, Inc. | 1 | $17 |
| NEW World Medical,inc. | 1 | $14 |
| Rayner Intraocular Lenses Limited | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Humphrey HFA$28,950
- IOLMaster 500$27,950
- Rocklatan$16,326
- Rhopressa$16,204
- VYZULTA$4,800
- Tecnis Symfony IOL$932
- TYRVAYA$125
- Voyager DSLT$122
- DURYSTA$121
- TRAVATAN Z$113
- CATALYS SYSTEM$110
How this compares
$87,513 in reported general payments places this provider in the 95th percentile of 2,513 ophthalmology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 607 | $301,486 |
| RocklatanNetarsudil Mesylat/Latanoprost | 289 | $160,667 |
| CombiganBrimonidine Tartrate/Timolol | 85 | $43,892 |
| Alphagan PBrimonidine Tartrate | 72 | $35,445 |
| VyzultaLatanoprostene Bunod | 55 | $33,749 |
| CequaCyclosporine | 22 | $29,355 |
| RestasisCyclosporine | 17 | $26,339 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 62 | $17,352 |
| Brimonidine Tartrate | 180 | $17,179 |
| Cyclosporine | 19 | $16,890 |
| Brinzolamide | 96 | $15,589 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 85 | $14,926 |
| MieboPerfluorohexyloctane/Pf | 13 | $12,710 |
| Latanoprost | 985 | $12,627 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 575 | $11,772 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Combigan, Alphagan P, Restasis | $2,088 | $407,162781 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $10,546 | $171,617304 claims |
| Bausch & Lomb Americas Inc.Vyzulta, Miebo | $331 | $46,45968 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $396 | $29,35522 claims |
| AlconSimbrinza | $6,874 | $17,35262 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Lotemax Sm | $5,237 | $11,02934 claims |
| Thea Pharma Inc.Iyuzeh | $138 | $8,12516 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,513 ophthalmology providers in California.
Other ophthalmology in San Ramon
- Daniel SchwartzSan Francisco$8M
- Michael BerlinWest Hollywood$5.7M
- Gilbert KlimanMenlo Park$1.5M
- Kuldev SinghStanford$1.5M
- Raymond DouglasBeverly Hills$1.3M
- John AffeldtLoma Linda$1.1M
- Srinivas SaddaPasadena$1M
- Sheri RowenNewport Beach$1M
- Savak TeymoorianLaguna Hills$955K
- Andrew MoshfeghiLos Angeles$895K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.